

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Gulfo Joseph V</u> (Last) (First) (Middle) <u>C/O ELECTRO-OPTICAL SCIENCES, INC.</u> <u>3 WEST MAIN ST. SUITE #201</u> (Street) <u>IRVINGTON NY 10533</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ELECTRO OPTICAL SCIENCES INC /NY</u> [<u>MELA</u>]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;"><u>CEO & President</u></p>
	3. Date of Earliest Transaction (Month/Day/Year) <u>05/22/2009</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
<u>Stock Option</u>	<u>\$3.75</u>	<u>10/10/2008</u>	<u>05/22/2009</u>	<u>A</u>		<u>180,000⁽¹⁾</u>		<u>10/10/2009</u>	<u>10/10/2018</u>	<u>Common Stock</u>	<u>180,000</u>	<u>\$3.75</u>	<u>180,000</u>	<u>D</u>	

Explanation of Responses:

1. On October 10, 2008, Dr. Gulfo was granted stock options for 900,000 shares of the Issuer's common stock. These shares have an exercise price of \$3.75 per share, which was the current market price at the date of the grant. This grant vests as follows: (i) with respect to 180,000 shares, immediately (the "Vested Shares"); (ii) with respect to 540,000 shares, upon the Issuer receiving approval from the Food and Drug Administration for a pre-market approval application for MelaFind; and (iii) with respect to 180,000 shares, in four equal annual installments commencing on October 10, 2009 (the "Annual Shares"). The Annual Shares were issued subject to stockholder approval, which was obtained at the Issuer's Annual Meeting held on May 22, 2009, and accordingly are now being reported in this Form 4. The Vested Shares were previously reported in a Form 4 filed with the SEC on October 15, 2008.

Remarks:

/s/ Philip DeBellis as attorney- 05/26/2009
in-fact for Joseph V. Gulfo

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.